Respiratory Syncytial Virus Prefusion F (RSVpreF) vaccination is efficient towards RSV-related decrease respiratory tract illness (LRTD) amongst adults aged 60 years or older, in line with a research revealed on-line Dec. 13 in JAMA Community Open.
Sara Y. Tartof, Ph.D., M.P.H., from Kaiser Permanente Southern California in Pasadena, and colleagues estimated RSVpreF vaccine effectiveness in older adults in a retrospective case-control research. Circumstances have been adults aged 60 years or older (imply age, 76.8 years) with hospitalizations or emergency division visits for LRTD from Nov. 24, 2023, to April 9, 2024, who had respiratory swabs collected and examined for RSV.
The research included 7,047 LRTD-related hospitalizations or emergency division encounters with RSV testing outcomes. Total, 14.2 % have been immunocompromised and 93.3 % had a number of Charlson comorbidity. The estimated adjusted vaccine effectiveness was 91 % utilizing a strict management definition that included RSV-negative LRTD occasions that have been damaging for human metapneumovirus, extreme acute respiratory syndrome coronavirus 2, and influenza and constructive for a non-vaccine-preventable trigger. Estimated adjusted vaccine effectiveness was 90 % utilizing a broad management definition, together with all RSV-negative LRTD occasions.
“Based on our study results and RSV incidence in older adults, for approximately every 250 persons vaccinated, one RSV-related emergency department or hospitalization encounter could be prevented in the first season after vaccination,” the authors write. “These data suggest use of RSVpreF in older adults, providing an opportunity to reduce severe medically attended RSV disease burden.”
A number of authors disclosed ties to biopharmaceutical firms, together with Pfizer, which manufactures the RSVpreF vaccine and funded the research.
Extra data:
Sara Y. Tartof et al, Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Associated Decrease Respiratory Tract Illness, JAMA Community Open (2024). DOI: 10.1001/jamanetworkopen.2024.50832
Quotation:
RSVpreF vaccine discovered efficient in stopping extreme RSV in older adults (2024, December 18)
retrieved 18 December 2024
from https://medicalxpress.com/information/2024-12-rsvpref-vaccine-effective-severe-rsv.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
